Bio-Rad Q1 sales down 3.3% to $676.8M; operating income drops 57.7% to $61.9M

BIO-RAD LABORATORIES, INC.

2023-Q1 EPS reported $2.32 revenue$676,844,000

Net sales $676.8M, down 3.3%; currency-neutral down 0.3%; ex-COVID up 6.1%.
GAAP diluted EPS $2.32 vs loss of $112.50; operating income $61.9M vs $146.4M.
Life Science sales $323.6M, down 6.8% (ex-COVID up 9.6% on qPCR, western blotting, ddPCR).
Clinical Diagnostics sales $352.1M flat; currency-neutral up 2.8% ex-COVID up 3.1%.
COVID sales dropped to $2.6M from $45M; gross margin fell to 53.5% from 57.5%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIO-RAD LABORATORIES, INC. reported the first quarter ended March 31, 2023 results: revenue $676.8 million, net income $69 million, EPS $2.32 per diluted share.

Period: the first quarter ended March 31, 2023
Revenue: $676.8 million
Net income: $69 million
EPS: $2.32 per diluted share
Result: reported results

Exact text from the filing

First-quarter 2023 net sales were $676.8 million, a decrease of 3.3 percent compared to $700.1 million reported for the first quarter of 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO-RAD LABORATORIES, INC. filing history →

Source: SEC EDGAR

accession 0000012208-23-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.